Key result
Seroprevalence rates against EV71 and CoxA16 were low under 1 year of age and showed an age-dependent increase, reaching 52.5-62.5% between 4 and 10 years of age.
Cross-Sectional (n=880)
Yes
Answers are grounded in this paper and cite their sources.
Seroepidemiology reveals low EV71 and CoxA16 neutralizing antibodies in infants under 1 year, suggesting the optimal window for vaccination is 4 to 11 months of age.
BACKGROUND: The major etiology of hand, foot and mouth disease (HFMD) is infection with human enterovirus A (HEV-A). Among subtypes of HEV-A, coxsackievirusA16 (CoxA16) and enterovirus 71 (EV71) are major causes for recurrent HFMD among infants and children in Jiangsu Province, mainland China. Here, we analyzed maternal antibodies between prenatal women and their neonates, to determine age-specific seroprevalence of human EV71 and CoxA16 infections in infants and children aged 0 to 15 years. The results may facilitate the development of immunization against HFMD. METHODS: This study used cross-section of 40 pairs of pregnant women and neonates and 800 subjects aged 1 month to 15 years old. Micro-dose cytopathogenic effects measured neutralizing antibodies against EV71 and CoxA16. Chi-square test compared seroprevalence rates between age groups and McNemar test, paired-Samples t-test and independent-samples t-test analyzed differences of geometric mean titers. RESULTS: A strong correlation between titers of neutralizing antibody against EV71 and CoxA16 in prenatal women and neonates was observed (rEV71 = 0.67, rCoxA16 = 0.56, respectively, p < 0.05). Seroprevalence rates of anti-EV71 antibody gradually decreased with age between 0 to 6 months old, remained low between 7 to 11 months (5.0-10.0%), and increased between 1 and 4 years (22.5-87.5%). Age-specific seroprevalence rates of anti-EV71 antibody stabilized in >80% of children between 5 to 15 years of age. However, seroprevalence rates of anti-CoxA16 antibody were very low (0.0-13.0%) between 0 to 6 months of age, gradually increased between 7 months to 4 years (15.0-70.0%), and stabilized at 54.0% (108/200) between 5 to 15 years. Seroprevalence rates against EV71 and CoxA16 were low under 1 year (0.0-10.0%), and showed an age dependent increase with high seroprevalence (52.5-62.5%) between 4 and 10 years of age. CONCLUSIONS: Concomitant infection of EV71 and CoxA16 was common in Jiangsu Province. Therefore, development of bivalent vaccine against both EV71 and CoxA16 is critical. The optimal schedule for vaccination may be 4 to11 months of age.
No takes yet. Share an insight, caveat, or question.
Ji et al. (2012) conducted a cross-sectional in Hand, foot and mouth disease (EV71 and CoxA16 infection) (n=880). Age and maternal antibody transfer was evaluated on Correlation between titers of neutralizing antibody against EV71 in prenatal women and neonates (r = 0.67, p=<0.05). Seroprevalence rates against EV71 and CoxA16 were low under 1 year of age and showed an age-dependent increase, reaching 52.5-62.5% between 4 and 10 years of age.
Synapse has enriched 10 related papers. Consider them for comparative context: